TD Cowen initiated coverage on Lantheus Holdings with a new price target
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
TD Cowen initiated coverage of Lantheus Holdings with a rating of Outperform and set a new price target of $100.00